Citations

Clear

25 citation(s) found for "Sj, Pandol".

Acute Pancreatitis Task Force on Quality: Development of Quality Indicators for Acute Pancreatitis Management
Vivian, Elaina , Cler, Leslie, Conwell, Darwin L. , Coté, Gregory A. , Dickerman, Richard, Freeman, Martin L. , Gardner, Timothy B. , Hawes, Robert H. , Kedia, Prashant , Krishnamoorthi, Rajesh , Oduor, Hellen , Ross, Andrew , Sethi, Amrita , Varadarajulu, Shyam , Vege, Santhi Swaroop , Wassef, Wahid , Wilcox, C. Mel, Yadav, Dhiraj , Ellison, Ashton , Habash, Samar, Rastegari, Sheila , Reddy, Rathan , Yen, Timothy , Tarnasky, Paul R., Pandol, Stephen J. , Papachristou, Georgios I. , Whitcomb, David C. , Wu, Bechien U. , Brooks, Mary Rachel

Mayo Clinic

American Journal of Gastroenterology | June 14, 2019 | Volume: 114 | Issue: 8 | Pages: 1322-1342

10.14309/ajg.0000000000000264 | PMID 31205135 Get It

INTRODUCTION: Detailed recommendations and guidelines for acute pancreatitis (AP) management currently exist. However, quality indicators (QIs) are required to measure performance in health care. The goal of the Acute Pancreatitis Task Force on Quality was to formally develop QIs for the management of patients with known or suspected AP using a modified version of the RAND/UCLA Appropriateness Methodology. METHODS: A multidisciplinary expert panel composed of physicians (gastroenterologists, hospitalists, and surgeons) who are acknowledged leaders in their specialties and who represent geographic and practice setting diversity was convened. A literature review was conducted, and a list of proposed QIs was developed. In 3 rounds, panelists reviewed literature, modified QIs, and rated them on the basis of scientific evidence, bias, interpretability, validity, necessity, and proposed performance targets. RESULTS: Supporting literature and a list of 71 proposed QIs across 10 AP domains (Diagnosis, Etiology, Initial Assessment and Risk Stratification, etc.) were sent to the expert panel to review and independently rate in round 1 (95% of panelists participated). Based on a round 2 face-to-face discussion of QIs (75% participation), 41 QIs were classified as valid. During round 3 (90% participation), panelists rated the 41 valid QIs for necessity and proposed performance thresholds. The final classification determined that 40 QIs were both valid and necessary. DISCUSSION: Hospitals and providers managing patients with known or suspected AP should ensure that patients receive high-quality care and desired outcomes according to current evidence-based best practices. This physician-led initiative formally developed 40 QIs and performance threshold targets for AP management. Validated QIs provide a dependable quantitative framework for health systems to monitor the quality of care provided to patients with known or suspected AP.
Standard Operating Procedures for Biospecimen Collection, Processing, and Storage
Fisher, William E., Cruz‐Monserrate, Zobeida , McElhany, Amy L., Hart, Phil A. , Ghosh, Ria , Buren, George Van , Fishman, Douglas S., Rinaudo, Jo Ann, Serrano, José , Srivastava, Sudhir , Mace, Thomas A. , Topazian, Mark , Feng, Ziding , Yadav, Dhiraj , Hughes, Steven J. , Liu, Robert Y., Lu, Emily Y., Orr, Robert Scott, Abouhamze, Amer, Troendle, David M. , Uç, Aliye , Lowe, Mark E. , Conwell, Darwin L. , Whitcomb, David C. , Serrano, Jose , Lesinski, Gregory B , Ghosh, Ria, Pandol, Stephen J. , Orr, Robert, Steen, Hanno , Sellers, Zachary M.

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1213-1221

10.1097/mpa.0000000000001171 | PMID 30325860 Get It

Abstract High-quality and well-annotated biorepositories are needed to better understand the pathophysiology and biologic mechanisms of chronic pancreatitis (CP) and its consequences. We report a methodology for the development of a robust standard operating procedure (SOP) for a biorepository based on the experience of the clinical centers within the consortium to study Chronic Pancreatitis, Diabetes and Pancreas Cancer Clinical Centers (CPDPC), supported by the National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases as a unique multidisciplinary model to study CP, diabetes, and pancreatic cancer in both children and adults. Standard operating procedures from the CPDPC centers were evaluated and consolidated. The literature was reviewed for standard biorepository operating procedures that facilitated downstream molecular analysis. The existing literature on biobanking practices was harmonized with the SOPs from the clinical centers to produce a biorepository for pancreatic research. This article reports the methods and basic principles behind the creation of SOPs to develop a biorepository for the CPDPC. These will serve as a guide for investigators developing biorepositories in pancreas research. Rigorous and meticulous adherence to standardized biospecimen collection will facilitate investigations to better understand the pathophysiology and biologic mechanisms of CP, diabetes, and pancreatic cancer.
PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Yadav, Dhiraj , Park, Walter G. , Fogel, Evan L. , Li, Liang , Chari, Suresh T. , Feng, Ziding , Fisher, William E., Forsmark, Christopher E., Habtezion, Aida , Hart, Phil A. , Hughes, Steven J. , Othman, Mohamed O. , Rinaudo, Jo Ann, Serrano, José , Srivastava, Sudhir , Topazian, Mark , Conwell, Darwin L. , Serrano, Jose , Jeon, Christie Y. , Pandol, Stephen J. , Tirkes, Temel , Van Den Eeden, Stephen K , Whitcomb, David C. , Chari, Suresh T

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1229-1238

10.1097/mpa.0000000000001170 | PMID 30325862 Get It

Abstract Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP—controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.
A Prospective Study to Establish a New-Onset Diabetes Cohort
Sharma, Ayush , Fisher, William E., Hart, Phil A. , Hughes, Steven J. , Mather, Kieren J., Park, Walter G. , Feng, Ziding , Serrano, José , Rinaudo, Jo Ann, Srivastava, Sudhir , Chari, Suresh T. , Serrano, Jose , Maitra, Anirban , Brand, Randall E. , Van Den Eeden, Stephen K , Pandol, Stephen J. , Chari, Suresh T

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1244-1248

10.1097/mpa.0000000000001169 | PMID 30325864 Get It

Abstract The National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases initiated the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) in 2015 (the CPDPC's origin, structure, governance, and research objectives are described in another article in this journal). One of the key objectives of CPDPC is to assemble a cohort of 10,000 subjects 50 years or older with new-onset diabetes, called the NOD cohort. Using a define, enrich, and find early detection approach, the aims of the NOD study are to ( a ) estimate the 3-year probability of pancreatic ductal adenocarcinoma (PDAC) in NOD ( define ), (b) establish a biobank of clinically annotated biospecimens from presymptomatic PDAC and control new-onset type 2 diabetes mellitus subjects, (c) conduct phase 3 validation studies of promising biomarkers for identification of incident PDAC in NOD patients ( enrich ), and (d) provide a platform for development of a future interventional screening protocol for early detection of PDAC in patients with NOD that incorporates imaging studies and/or clinical algorithms ( find ). It is expected that 85 to 100 incidences of PDAC will be diagnosed during the study period in this cohort of 10,000 patients.
Pancreatic Cancer Following Incident Diabetes in African Americans and Latinos: The Multiethnic Cohort
Porcel, Jacqueline , Chari, Suresh T. , Haiman, Christopher A. , Setiawan, Veronica Wendy , Stram, Daniel O. , Maskarinec, Gertraud , Marchand, Loı̈c Le , Wilkens, Lynne R. , Pandol, Stephen J. , Monroe, Kristine R. , Chari, Suresh T

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 18, 2018 | Volume: 111 | Issue: 1 | Pages: 27-33

10.1093/jnci/djy090 | PMID 29917105 Get It